Clinical Trial Detail

NCT ID NCT03370185
Title Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors Verastem, Inc.
Indications

chronic lymphocytic leukemia

CLL/SLL

Therapies

Duvelisib

Age Groups: adult senior

No variant requirements are available.